Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies that are designed to harness the immune system to attack cancer cells. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that is in Phase I/Ib clinical trial for adenosine, an immune checkpoint. The company is also developing an anti-CD73 monoclonal antibody that inhibits the production of adenosine; an antagonist of the adenosine A2B receptor; and small molecule covalent inhibitors of interleukin-2 inducible kinase. Corvus Pharmaceuticals, Inc. was founded in 2014 and is based in Burlingame, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CRVS
Previous Symbol
CUSIPN/A
Phone650-900-4520
Debt
Debt-to-Equity RatioN/A
Current Ratio16.09
Quick Ratio16.09
Price-To-Earnings
Trailing P/E Ratio-1.79
Forward P/E Ratio-2.75
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value$4.03 per share
Price / Book1.21
Profitability
EPS (Most Recent Fiscal Year)($2.72)
Net Income$-55,660,000.00
Net MarginsN/A
Return on Equity-41.31%
Return on Assets-38.03%
Miscellaneous
Employees55
Outstanding Shares29,280,000
Market Cap$147.58 million
OptionableNot Optionable
Corvus Pharmaceuticals (NASDAQ:CRVS) Frequently Asked Questions
What is Corvus Pharmaceuticals' stock symbol?
Corvus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRVS."
How were Corvus Pharmaceuticals' earnings last quarter?
Corvus Pharmaceuticals Inc (NASDAQ:CRVS) issued its earnings results on Thursday, November, 1st. The company reported ($0.36) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.48) by $0.12. View Corvus Pharmaceuticals' Earnings History.
When is Corvus Pharmaceuticals' next earnings date?
What price target have analysts set for CRVS?
4 brokerages have issued twelve-month price objectives for Corvus Pharmaceuticals' stock. Their predictions range from $15.00 to $17.00. On average, they expect Corvus Pharmaceuticals' share price to reach $16.00 in the next twelve months. This suggests a possible upside of 228.5% from the stock's current price. View Analyst Price Targets for Corvus Pharmaceuticals.
What is the consensus analysts' recommendation for Corvus Pharmaceuticals?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corvus Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Corvus Pharmaceuticals.
Has Corvus Pharmaceuticals been receiving favorable news coverage?
News headlines about CRVS stock have trended somewhat positive this week, InfoTrie reports. The research group scores the sentiment of news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Corvus Pharmaceuticals earned a media sentiment score of 1.7 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 1.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the immediate future.
Are investors shorting Corvus Pharmaceuticals?
Corvus Pharmaceuticals saw a decrease in short interest during the month of November. As of November 30th, there was short interest totalling 785,077 shares, a decrease of 26.5% from the November 15th total of 1,067,758 shares. Based on an average trading volume of 72,950 shares, the short-interest ratio is currently 10.8 days. Currently, 4.0% of the shares of the company are short sold. View Corvus Pharmaceuticals' Current Options Chain.
Who are some of Corvus Pharmaceuticals' key competitors?
Some companies that are related to Corvus Pharmaceuticals include Eidos Therapeutics (EIDX), Karyopharm Therapeutics (KPTI), Inflarx (IFRX), AMAG Pharmaceuticals (AMAG), MacroGenics (MGNX), Arcus Biosciences (RCUS), Cara Therapeutics (CARA), CannTrust (CNTTF), Assembly Biosciences (ASMB), Ra Pharmaceuticals (RARX), NuCana (NCNA), Akorn (AKRX), Basilea Pharmaceutica (BPMUF), ChemoCentryx (CCXI) and Kura Oncology (KURA).
Who are Corvus Pharmaceuticals' key executives?
Corvus Pharmaceuticals' management team includes the folowing people:
- Dr. Richard A. Miller, Co-Founder, Pres, CEO & Chairman (Age 67)
- Mr. Leiv Lea, Chief Financial Officer (Age 64)
- Mr. Daniel W. Hunt J.D., Sr. VP & Chief Bus. Officer (Age 56)
- Dr. Joseph J. Buggy, Co-Founder & Exec. VP of Discovery Research (Age 51)
- Mr. Alan C. Mendelson Esq., Sec.
When did Corvus Pharmaceuticals IPO?
(CRVS) raised $75 million in an initial public offering on Wednesday, March 23rd 2016. The company issued 4,700,000 shares at $15.00-$17.00 per share. Credit Suisse and Cowen and Company acted as the underwriters for the IPO and Guggenheim Securities, Cantor Fitzgerald and BTIG were co-managers.
Who are Corvus Pharmaceuticals' major shareholders?
Corvus Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include FMR LLC (6.89%), BlackRock Inc. (4.12%), Vanguard Group Inc. (2.32%), Vanguard Group Inc (2.32%), Renaissance Technologies LLC (1.36%) and EcoR1 Capital LLC (1.20%). Company insiders that own Corvus Pharmaceuticals stock include Adams Street Partners Llc, Holdings A/S Novo and Richard A Md Miller. View Institutional Ownership Trends for Corvus Pharmaceuticals.
Which institutional investors are selling Corvus Pharmaceuticals stock?
Which institutional investors are buying Corvus Pharmaceuticals stock?
CRVS stock was acquired by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, BlackRock Inc., Renaissance Technologies LLC, Hikari Power Ltd, Credit Suisse AG, Citadel Advisors LLC, Bridgeway Capital Management Inc. and Vanguard Group Inc. Company insiders that have bought Corvus Pharmaceuticals stock in the last two years include Adams Street Partners Llc, Holdings A/S Novo and Richard A Md Miller. View Insider Buying and Selling for Corvus Pharmaceuticals.
How do I buy shares of Corvus Pharmaceuticals?
Shares of CRVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Corvus Pharmaceuticals' stock price today?
One share of CRVS stock can currently be purchased for approximately $4.87.
How big of a company is Corvus Pharmaceuticals?
Corvus Pharmaceuticals has a market capitalization of $147.58 million. The company earns $-55,660,000.00 in net income (profit) each year or ($2.72) on an earnings per share basis. Corvus Pharmaceuticals employs 55 workers across the globe.
What is Corvus Pharmaceuticals' official website?
How can I contact Corvus Pharmaceuticals?
Corvus Pharmaceuticals' mailing address is 863 Mitten Road Suite102, BURLINGAME CA, 94010. The company can be reached via phone at 650-900-4520 or via email at [email protected]
MarketBeat Community Rating for Corvus Pharmaceuticals (NASDAQ CRVS)
MarketBeat's community ratings are surveys of what our community members think about Corvus Pharmaceuticals and other stocks. Vote "Outperform" if you believe CRVS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRVS will underperform the S&P 500 over the long term. You may vote once every thirty days.
